WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H525570
CAS#: 147523-65-7
Description: LY-288513 is a selective CCK2 receptor antagonist (IC50 values are 16 and > 30,000 nM for CCK2 and CCK1 respectively). LY-288513 displays anxiolytic and antipsychotic properties in vivo.
Hodoodo Cat#: H525570
Name: LY-288513
CAS#: 147523-65-7
Chemical Formula: C22H18BrN3O2
Exact Mass: 435.06
Molecular Weight: 436.310
Elemental Analysis: C, 60.56; H, 4.16; Br, 18.31; N, 9.63; O, 7.33
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: LY-288513; LY 288513; LY288513.
IUPAC/Chemical Name: 1-Pyrazolidinecarboxamide, N-(4-bromophenyl)-3-oxo-4,5-diphenyl-, (4S,5R)-
InChi Key: LMUQHXHWJWQXSD-PMACEKPBSA-N
InChi Code: InChI=1S/C22H18BrN3O2/c23-17-11-13-18(14-12-17)24-22(28)26-20(16-9-5-2-6-10-16)19(21(27)25-26)15-7-3-1-4-8-15/h1-14,19-20H,(H,24,28)(H,25,27)/t19-,20-/m0/s1
SMILES Code: O=C(N1NC([C@@H](C2=CC=CC=C2)[C@@H]1C3=CC=CC=C3)=O)NC4=CC=C(Br)C=C4
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 436.31 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Zhang JG, Liu JX, Jia XX, Geng J, Yu F, Cong B. Cholecystokinin octapeptide regulates the differentiation and effector cytokine production of CD4(+) T cells in vitro. Int Immunopharmacol. 2014 Jun;20(2):307-15. doi: 10.1016/j.intimp.2014.03.013. Epub 2014 Apr 2. PubMed PMID: 24704498.
2: Yu H, Wen D, Ma C, Meng Y, Li S, Ni Z, Cong B. Effects of exogenous cholecystokinin octapeptide on acquisition of naloxone precipitated withdrawal induced conditioned place aversion in rats. PLoS One. 2012;7(7):e41860. doi: 10.1371/journal.pone.0041860. Epub 2012 Jul 27. PubMed PMID: 22848639; PubMed Central PMCID: PMC3407117.
3: Farook JM, Zhu YZ, Wang Q, Moochhala SM, Lee L, Wong PT. Analysis of strain difference in behavior to Cholecystokinin (CCK) receptor mediated drugs in PVG hooded and Sprague-Dawley rats using elevated plus-maze test apparatus. Neurosci Lett. 2004 Apr 1;358(3):215-9. PubMed PMID: 15039119.
4: Belzung C, Le Guisquet AM, Barreau S, Calatayud F. An investigation of the mechanisms responsible for acute fluoxetine-induced anxiogenic-like effects in mice. Behav Pharmacol. 2001 Jun;12(3):151-62. PubMed PMID: 11485052.
5: Sitthisomwong P, Weiner S, Levin L, Reisman S, Siegel A. The effect of a cholecystokinin agonist on masseter muscle activity in the cat. J Dent Res. 2000 Oct;79(10):1823-8. PubMed PMID: 11078001.
6: Bourin M, Malinge M, Colombel MC, Vasar E. Cholecystokinin receptor agonists block the jumping behaviour precipitated in morphine-dependent mice by naloxone. Eur Neuropsychopharmacol. 1999 Jan;9(1-2):37-43. PubMed PMID: 10082226.
7: Izumi T. [Behavioral and neurochemical study on the role of the brain cholecystokinin system in anxiety]. Hokkaido Igaku Zasshi. 1998 Sep;73(5):463-73. Japanese. PubMed PMID: 9846276.
8: Griebel G, Perrault G, Sanger DJ. CCK receptor antagonists in animal models of anxiety: comparison between exploration tests, conflict procedures and a model based on defensive behaviours. Behav Pharmacol. 1997 Nov;8(6-7):549-60. PubMed PMID: 9832969.
9: Luo B, Cheu JW, Siegel A. Cholecystokinin B receptors in the periaqueductal gray potentiate defensive rage behavior elicited from the medial hypothalamus of the cat. Brain Res. 1998 Jun 15;796(1-2):27-37. PubMed PMID: 9689451.
10: Adamec RE, Shallow T, Budgell J. Blockade of CCK(B) but not CCK(A) receptors before and after the stress of predator exposure prevents lasting increases in anxiety-like behavior: implications for anxiety associated with posttraumatic stress disorder. Behav Neurosci. 1997 Apr;111(2):435-49. PubMed PMID: 9106682.
11: Blacker D, Broberger C, Ogren SO, Hökfelt T. Cholecystokinin B receptor antagonists enhance the locomotor response to the N-methyl-D-aspartate antagonists phencyclidine and dizocilpine maleate. Neuroscience. 1997 Feb;76(4):1057-67. PubMed PMID: 9027866.
12: Rasmussen K, Gates MR, Burger JE, Czachura JF. The novel atypical antipsychotic olanzapine, but not the CCK-B antagonist LY288513, blocks apomorphine-induced disruption of pre-pulse inhibition. Neurosci Lett. 1997 Jan 24;222(1):61-4. PubMed PMID: 9121724.
13: Ding XQ, Håkanson R. Evaluation of the specificity and potency of a series of cholecystokinin-B/gastrin receptor antagonists in vivo. Pharmacol Toxicol. 1996 Sep;79(3):124-30. Erratum in: Pharmacol Toxicol 1997 May;80(5):254. PubMed PMID: 8884870.
14: Dunlop J, Brammer N, Ennis C. Pharmacological characterization of a Chinese hamster ovary cell line transfected with the human CCK-B receptor gene. Neuropeptides. 1996 Aug;30(4):359-63. PubMed PMID: 8914862.
15: Rasmussen K, Czachura JF, Kallman MJ, Helton DR. The CCK-B antagonist LY288513 blocks the effects of nicotine withdrawal on auditory startle. Neuroreport. 1996 Apr 10;7(5):1050-2. PubMed PMID: 8804049.
16: Izumi T, Inoue T, Tsuchiya K, Hashimoto S, Ohmori T, Koyama T. Effect of the selective CCKB receptor antagonist LY288513 on conditioned fear stress in rats. Eur J Pharmacol. 1996 Apr 4;300(1-2):25-31. PubMed PMID: 8741161.
17: Helton DR, Berger JE, Czachura JF, Rasmussen K, Kallman MJ. Central nervous system characterization of the new cholecystokininB antagonist LY288513. Pharmacol Biochem Behav. 1996 Mar;53(3):493-502. PubMed PMID: 8866946.
18: Harro J, Oreland L, Vasar E, Bradwejn J. Impaired exploratory behaviour after DSP-4 treatment in rats: implications for the increased anxiety after noradrenergic denervation. Eur Neuropsychopharmacol. 1995 Dec;5(4):447-55. PubMed PMID: 8998396.
19: Woodland JM, Ehlhardt WJ. Characterization of an O-glucuronide metabolite of the CCK-B antagonist LY288513 and its plasma levels in mouse, rat, and dog. Drug Metab Dispos. 1995 Sep;23(9):910-5. PubMed PMID: 8565780.
20: Lemaire M, Böhme GA, Piot O, Roques BP, Blanchard JC. CCK-A and CCK-B selective receptor agonists and antagonists modulate olfactory recognition in male rats. Psychopharmacology (Berl). 1994 Aug;115(4):435-40. PubMed PMID: 7871086.
